DCISionRT and its Response Subtype Identifies DCIS Patients with Unacceptably Elevated Risk of Local Recurrence after Breast Conserving Surgery and Radiation Therapy
/PRNewswire/ Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, presented data in an.
/PRNewswire/ Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today.
/PRNewswire/ Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today.
PreludeDx Appoints Dr. Karuna Mittal, Director, Research and Development prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.